时间标签：数据日期 2026-10-31 · 生成时间 2026-11-01 05:30（Asia/Shanghai）｜ 检索窗口 PubMed edat 2026/10/28–2026/10/31 ｜ 情报发生日期 2026-10-31
研究问题
Bevacizumab, although used off-label, remains widely used in clinical practice due to its cost-effectiveness and broad accessibility.；However, most available evidence concerns the reference molecule, and prospective real-world data evaluating the switch to aflibercept biosimilars remain limited.；Interchangeability is, however, a jurisdiction-specific regulatory concept.
方法
This prospective, single-center, single-arm interventional cohort study was conducted at a tertiary ophthalmology clinic.；The study protocol was approved by the Afyonkarahisar Health Sciences University Ethics Committee before patient enrollment (approval number: 26/3-221).；Written informed consent was obtained from all participants before enrollment and treatment initiation.；Switching eligibility was prospectively defined and applied uniformly to all participants.
核心结论
All MNV eyes were associated with neovascular age-related macular degeneration; no myopic, pachychoroid-related, or other secondary MNV etiologies were included.；All eyes in this subgroup had received three consecutive monthly bevacizumab injections before the preswitch baseline assessment, and none had previously received ranibizumab or aflibercept.；Previous focal or panretinal laser photocoagulation had been performed in 30 eyes (56.6%). ‖ 结论：In conclusion, administration of aflibercept-jbvf following three monthly bevacizumab injections was temporally associated with a statistically significant but modest very early reduction in CST at 4 weeks in eyes with DME, MNV, and RVO.
局限
Direct comparison with these studies should also be interpreted with caution because of differences in study populations, baseline disease severity, follow-up duration, treatment exposure, and outcome metrics.；The inclusion of DME, MNV, and RVO within the same cohort represents both a pragmatic strength and an important interpretative limitation.；Disease-specific findings may be more clinically informative, although all subgroup analyses were exploratory and underpowered.
对本项目的价值
★☆☆☆☆ 皮肤是唯一可直接局部给药、可活检、可影像量化的器官，最快可验证 senotherapeutic 概念。
全文来源
PMC JATS 全文（正文 35,262 字符，已过标题/DOI 逐字归属校验）
原文题录
- 英文标题：Early outcomes of switching from bevacizumab to aflibercept-jbvf in exudative macular diseases: a real-world study.
- 期刊与标识：BMC Ophthalmol · PMID 42958502 · DOI 10.1186/s12886-026-05491-4
A 级证据分级：A 级（同行评议人体研究）
本文属人体研究证据，但需注意：观察性或小样本干预的结论不等于已证实临床获益；效应量与长期安全性仍需更大规模、更长随访的试验验证。
关于本文的文献来源：本站依据 IMA 知识库「五刊监控·深度文献卡片」撰写，依据已获取的期刊全文（方法、样本量与结论已回到原文核对）；未能获取全文的同批条目另行标注「摘要级」，全程未做任何数值推算补全。